Video

TEAM Trial

Publish date: January 7, 2009

 

Dr. Stephen Jones discusses TEAM trial findings that suggest exemestane improves breast cancer survival over tamoxifen at 2.75 years of follow-up. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.

Recommended Reading

No Radiation After Breast-Conserving Surgery?
Breast Cancer ICYMI
Breast-Specific Gamma Imaging
Breast Cancer ICYMI
QDoes postmenopausal use of unopposed estrogen increase the risk of breast cancer?
Breast Cancer ICYMI
Q.HT and breast cancer: Does the type of progestin matter?
Breast Cancer ICYMI
Atypical Presentation of Infiltrating Mucinous Carcinoma of the Breast
Breast Cancer ICYMI
Keeping Breast Cancer at Bay
Breast Cancer ICYMI